（文章来源：证券日报） 证券日报网讯 9月16日晚间，济川药业发布公告称，近日，公司全资子公司陕西东科制药有限责任公司 （简称"陕西东科"）收到利多卡因凝胶贴膏《药品注册证书》。 ...

每经AI快讯，济川药业（SH 600566，收盘价：25.54元）9月16日晚间发布公告称，近日，湖北济川药 业股份有限公司全资子公司陕西东科制药有限责任公司收到国家药品监督管理局核准签发的利多卡因凝 胶贴膏《药品注册证书》。 2024年1至12月份，济川药业的营业收入构成为：清热解毒类占比33.53%，儿科类占比28.11%，消化类 占比14.41%，其他行业占比9.94%，呼吸类占比8.13%。 截至发稿，济川药业市值为235亿元。 每经头条（nbdtoutiao）——海拔4306米现"秦始皇密令"，获官方"身份认定"！古文字学家刘钊：秦人 寻仙采药足迹确至青藏高原 （记者 王晓波） ...

济川药业（600566）(600566.SH)公告，公司全资子公司陕西东科制药有限责任公司(简称"陕西东科")收 到国家药品监督管理局核准签发的利多卡因凝胶贴膏《药品注册证书》。利多卡因是一种酰胺类局部麻 醉剂，通过抑制神经冲动发生与传导所需的离子通道而起到稳定神经细胞膜作用。 ...

每经AI快讯，9月16日，济川药业(600566.SH)公告称，公司全资子公司陕西东科收到国家药监局核准签 发的利多卡因凝胶贴膏《药品注册证书》。该药品用于缓解带状疱疹后神经痛，用于无破损皮肤。截至 目前，国内已有4家企业（含陕西东科）获批利多卡因凝胶贴膏。此次获得证书是对公司产品的进一步 补充，预计将对公司今后的发展起到积极作用。但药品上市需要市场开发周期，且易受行业政策、招标 采购等因素影响，存在不确定性。 （文章来源：每日经济新闻） ...

智通财经APP讯，济川药业(600566.SH)公告，公司全资子公司陕西东科制药有限责任公司(简称"陕西东 科")收到国家药品监督管理局核准签发的利多卡因凝胶贴膏《药品注册证书》。利多卡因是一种酰胺类 局部麻醉剂，通过抑制神经冲动发生与传导所需的离子通道而起到稳定神经细胞膜作用。 ...

格隆汇9月16日丨济川药业(600566.SH)公布，公司全资子公司陕西东科制药有限责任公司（称"陕西东 科"）收到国家药品监督管理局核准签发的利多卡因凝胶贴膏《药品注册证书》，利多卡因是一种酰胺 类局部麻醉剂，通过抑制神经冲动发生与传导所需的离子通道而起到稳定神经细胞膜作用。 ...

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Lidocaine Gel Patch, indicating a significant regulatory approval for a new product aimed at treating postherpetic neuralgia [1] Group 1: Product Details - The drug is named Lidocaine Gel Patch, classified as a Class 3 chemical drug [1] - The formulation is a patch with dimensions of 14cm x 10cm, containing 14g of gel and 700mg of Lidocaine per patch [1] - The product is specifically indicated for alleviating pain associated with postherpetic neuralgia and is suitable for use on intact skin [1]

Group 1: Company Strategy and Market Positioning - The company is focusing on three key areas for future strategic planning: expanding sales channels, increasing R&D efforts, and optimizing production processes to enhance operational efficiency and shareholder value [2] - The company aims to strengthen its presence in the outpatient market while enhancing brand influence, particularly for the "JiuYue" transdermal patch brand [3] - The company plans to launch several transdermal products, including Lidocaine Gel Patch and Indomethacin Gel Patch, expected to be approved in 2025, and Ketoprofen Patch and Flurbiprofen Patch in 2026 [4] Group 2: Product Development and Competition - The company believes that the market for external anti-inflammatory drugs is currently underserved, and the two products, Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, will complement each other rather than compete [7] - The Loxoprofen Sodium Gel Patch has a high drug loading of 100mg per patch and is suitable for a wide range of conditions, while the Ketoprofen Gel Patch offers better drug permeability and efficacy for osteoarthritis [5] Group 3: Financial Projections and Market Risks - The company projects a revenue growth of 10-20% for the fiscal year 2025, with a similar expectation for net profit excluding non-recurring items [11][12] - The company acknowledges that its operational plans and product sales depend on various factors, including market conditions and industry policies, which introduce significant uncertainty [12] Group 4: Cost Management and Procurement Strategy - The company plans to reduce sales expenses by optimizing marketing strategies and expanding outpatient market reach [2] - The company maintains an integrated development strategy for raw materials and finished products, ensuring quality control and cost management through in-house production [10]